However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda ...

CytomX Therapeutics is testing CX-801 with Keytruda in a phase 1 trial for metastatic melanoma, focusing on safety and clinical activity. The trial is conducted at UCSF and the University of ...

Evorpacept and Keytruda combination failed to meet primary endpoints in ASPEN-03 and ASPEN-04 trials for advanced HNSCC. The combination did not improve objective response rates compared to historical ...

Dosage for Keytruda may vary based on the condition it’s being used to treat. The typical starting dose is 200 mg every 3 weeks or 400 mg every 6 weeks. Your doctor may adjust your dosage.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said. Merck said last week its biggest ...

Merck’s Keytruda is the world’s top-selling drug, bringing in nearly $30 billion in sales last year. The drug, which is used to treat lung cancer, melanoma and certain other cancers ...

Keytruda plus chemo showed meaningful PFS improvement in all patients, regardless of PD-L1 status. Overall survival benefit observed in PD-L1–positive tumors (CPS ≥1) compared to placebo-based ...

The facility’s products will include biologic drugs and a new, easier-to-use version of Keytruda, the company’s blockbuster cancer drug. The plant marks Merck’s first in-house manufacturing ...